Navigation Links
Karyopharm Therapeutics Inc. Appoints Michael Kauffman, MD, PhD, as Chief Executive Officer
Date:1/5/2011

NEWTON, Mass., Jan. 5, 2011 /PRNewswire/ -- Karyopharm Therapeutics Inc., a pioneer and leader in the new field of nuclear transport modulators, announces the recruitment of a highly experienced cancer drug developer, Michael G. Kauffman, MD, PhD, as its Chief Executive Officer. Dr. Kauffman will join Sharon Shacham, PhD, MBA, the Company's CSO and Head of Research and Development, as its executive management team. Kauffman's appointment follows the $20M Series A financing announced in November, 2010.

Karyopharm's lead program is focused on novel, small molecule SINE (Selective Inhibitors of Nuclear Export) targeting CRM1. CRM1 is a key linchpin governing the nuclear export of multiple tumor suppressors and growth regulatory proteins, providing a strategic point of therapeutic intervention for a diverse array of cancers. On joining Karyopharm, Kauffman, also a Karyopharm co-founder and Director, commented, "This is a rare opportunity to join a company firing on all cylinders -- strong funding, extremely promising lead compounds with broad and potent in vivo anti-tumor activity, a seasoned and committed scientific and development team, and leading cancer consultants. The clinical application, enabled further by sophisticated proprietary pharmacogenomic insights, offers the potential to transform cancer treatment with a new class of effective and well tolerated agents."  

According to Karyopharm Co-Founder, Board Member and Harvard cancer scientist Ronald A. DePinho, M.D., "The recruitment of Dr. Kauffman represents a major advance for Karyopharm which is now poised to bring a powerful new class of cancer medicines for diverse cancers and other diseases. Michael brings an extraordinary record of professional achievement in the development of major novel cancer drugs and in building and managing highly successful biotechnology companies."

Board member and clinical advisor Dr. Mansoor Raza Mirza commented, "It is depressing to see my patien
'/>"/>

SOURCE Karyopharm Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other Disorders
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014  VentiRx Pharmaceuticals, Inc., a clinical ... and commercialization of novel Toll-like receptor 8 ... Food and Drug Administration (FDA) has granted ... motolimod (VTX-2337) when administered in combination with ... of women with ovarian cancer whose disease ...
(Date:9/2/2014)...   Intrexon Corporation (NYSE: XON ... it has entered into an Exclusive Channel Collaboration (ECC) ... (EURONEXT: SAN and NYSE: SNY ) to ... of its marketed Active Pharmaceutical Ingredients (APIs) through Sanofi,s ... This collaboration will leverage Intrexon,s proprietary technology suite plus ...
(Date:9/2/2014)... , Sept. 2, 2014   Veracyte, Inc. (Nasdaq: ... Anderson , president and chief executive officer, will present in ... Healthcare Unplugged Conference 2014 on Monday, September 8, 2014 at ... The live audio webcast and subsequent replay may ... Please connect to the website at least 15 minutes prior ...
Breaking Medicine Technology:VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 2VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 3Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 2Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 3Veracyte to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2014 2
... YORK, Sept. 1, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0559262/Global-CRO-Market-Quantitative-Assessment.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development This ... globally, by phase and market type, R&D ...
... This evening, Novo Nordisk awarded sponsorships totaling ... that educate people living with type 2 diabetes on ... risk of long-term diabetes related complications. The sponsorships are ... aims to promote enduring, sustainable change for people living ...
Cached Medicine Technology:Global CRO Market: Quantitative Assessment 2Global CRO Market: Quantitative Assessment 3Novo Nordisk Partners with Minneapolis Community Groups to Support Diabetes Education Programs 2
(Date:9/2/2014)... 02, 2014 West Hollywood cosmetic ... consultations for Invisalign. This special offer includes a free ... to determine their candidacy for the procedure and answer ... patients may also be eligible for the Summer Invisalign ... of the month of August, patients who choose Invisalign ...
(Date:9/2/2014)... MONDAY, Sept. 1, 2014 (HealthDay News) -- The quality ... overall, and dietary disparity between the rich and poor ... provides the most direct evidence to date that the ... U.S. dietary quality are having some payoff, but it ... study author Dong Wang, a doctoral student in the ...
(Date:9/2/2014)... 2, 2014 (HealthDay News) -- When it comes to excess ... equal, a new study finds. The research found that ... person,s odds for high blood pressure more than overall body ... of high blood pressure. But it wasn,t clear how the ... to researchers at University of Texas Southwestern Medical Center in ...
(Date:9/2/2014)... Dallas, Texas (PRWEB) September 02, 2014 ... , “North America Resectoscopes Market Outlook to 2020? ... Resectoscopes market. The report provides value, in millions ... prices (in US dollars) within market segments –, ... Electrodes (Monopolar (Disposable and Reusable) Electrodes and Bipolar ...
(Date:9/2/2014)... USARAD Holdings Inc. a leading ... provider, including SecondOpinions.com® – consumer division is gaining ... services. The telemedicine industry pioneer is now partnering ... Founded and established in 1963 as the first ... as a maternity care hospital with very few ...
Breaking Medicine News(10 mins):Health News:West Hollywood Cosmetic Dentist, Dr. Poneh Ghasri, Now Offers Complimentary Consultations for Invisalign 2Health News:Quality of U.S. Diet Improves, Slightly 2Health News:'Spare Tire' May Be Especially Bad for Your Blood Pressure 2Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 2Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 3Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 4Health News:USARAD Holdings Inc. SECONDOPINIONS.COM® Partners With Prestigious Dar Al Shifa Hospital In Kuwait 2Health News:USARAD Holdings Inc. SECONDOPINIONS.COM® Partners With Prestigious Dar Al Shifa Hospital In Kuwait 3Health News:USARAD Holdings Inc. SECONDOPINIONS.COM® Partners With Prestigious Dar Al Shifa Hospital In Kuwait 4
... blockbuster drug and greater reimbursement levels for the treatment ... smoking cessation and addiction treatments are expected to ... 2005 to more than $2.3 billion in 2010, according ... Analysis, a new study released today from Kalorama Information. ...
... a computer based test that may reveal how easily an ... that her scientific test can be used as another ... in fields where employee distraction can lead to fatal errors. ... liable to do things like put your keys in the ...
... are hopeful that the actress' current rehab spell will bring ... wacky recent incidents . ,As the Mean Girls ... on May 28, after being arrested for DUI, her supposed ... ,One friend told America's Star magazine that Lohan ...
... of Illinois dentists provide oral cancer examinations for their ... thoroughly or at optimum intervals, according to a new ... of pre-malignant lesions and of proper examination techniques, some ... be doing to detect oral cancers in their patients," ...
... on Thursday announced that FDA has granted a standard ... Cervarix, Reuters reports. A GSK spokesperson on Thursday said ... been completed in six months. ,Cervarix and ... 100% effective in preventing infection with HPV strains 16 ...
... Dey, L.P. announced today that the U.S. Food ... Drug Application (NDA) of its marketing partner, Critical ... tablets. ZYFLO CR(TM) offers twice-daily, extended-release dosing. Under ... in March 2007, DEY will co-market Critical Therapeutics' ...
Cached Medicine News:Health News:Individuals Distraction can Be Measured by a Computer Based Test 2Health News:Dentists Need More Training in Oral Cancer Detection 2Health News:Dentists Need More Training in Oral Cancer Detection 3Health News:FDA Approves ZYFLO CR(TM) (Zileuton) for Chronic Treatment of Asthma 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: